SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-024943
Filing Date
2021-05-06
Accepted
2021-05-06 16:06:16
Documents
68
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aldx-10q_20210331.htm   iXBRL 10-Q 1895948
2 EX-31.1 aldx-ex311_6.htm EX-31.1 17219
3 EX-31.2 aldx-ex312_7.htm EX-31.2 17439
4 EX-32.1 aldx-ex321_9.htm EX-32.1 8999
  Complete submission text file 0001564590-21-024943.txt   6083565

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA aldx-20210331.xsd EX-101.SCH 45182
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aldx-20210331_cal.xml EX-101.CAL 41579
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aldx-20210331_def.xml EX-101.DEF 128509
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20210331_lab.xml EX-101.LAB 335181
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20210331_pre.xml EX-101.PRE 253317
10 EXTRACTED XBRL INSTANCE DOCUMENT aldx-10q_20210331_htm.xml XML 929660
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 21897710
SIC: 2834 Pharmaceutical Preparations